Navigation Links
Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
Date:7/28/2010

unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development, to expand manufacturing and commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; our failure
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
3. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
4. Angiotech Pharmaceuticals Announces Conference Call and Webcast
5. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
6. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
7. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
8. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
9. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
10. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
11. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... D.C., September 30, 2014 Applying a well-known ... researchers at Harvard University has demonstrated the ability ... -- work that holds promise for making future, ... detailing the sides of next-gen rocket ships and ... light passes through oil in water, it becomes ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... Proove Biosciences , the commercial and ... a new genetic test built upon research from their ... will provide physicians with an objective way to ... are stratified between individuals. With this new test, physicians ... a genetic predisposition that will affect their pain tolerance. ...
(Date:9/30/2014)... Hungary , September 30, 2014 ... and intuitive browsing of chemistry in documents ... chemistry software solutions and consulting services for life ... chemical information and generate Markush structures from documents. ... an organizations intellectual property, however generating and understanding ...
Breaking Biology Technology:Taking thin films to the extreme 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2
... , M. Adams ... NJ, US, , ... DNA and sequencing template preparation needs. A combination of these kits with the Genesis ... high-throughput DNA preparation. , ...
... <P , ,>O. Rönn 1 , M. Landström 2 , A. Edman-Örlefors 1 ... 1 GE Healthcare, Uppsala, Sweden , ... Research, Uppsala, Sweden , , ... proteins at picogram levels, with linearity over 3.6 orders of magnitude. Two antigens ...
... , ... assay • LEADseeker • SPA Imaging Beads , ... biogenic amine that plays important pathophysiological roles in central and peripheral tissues. ... that characterize allergic responses (1).The function of histamine is mediated via four ...
Cached Biology Technology:Automation of TempliPhi and GenomiPhi DNA Amplification Kits on the Genesis Freedom Robotic Sample Processor 2Automation of TempliPhi and GenomiPhi DNA Amplification Kits on the Genesis Freedom Robotic Sample Processor 3Detection and quantitation of low-abundant proteins with ECL Plex fluorescent Western blotting 2Detection and quantitation of low-abundant proteins with ECL Plex fluorescent Western blotting 3Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 2Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 3Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 4Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 5
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... available in German . ... response to risky situations such as exposure to predators. ... found in a long-term study on different populations of ... rate and ambient temperature. High metabolic rates and low ... these scenarios birds were more likely to approach potential ...
(Date:9/30/2014)... Ill. (September 30, 2014) People who suffer from ... do to control their asthma besides properly taking medications ... new article in the Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), asthma sufferers ... their lifestyle. The woman described in the Annals article ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... Researchers at the Tufts University School of Engineering ... first large area metamaterial structures patterned on implantable, ... July 21, 2010, in the journal Advanced ... development of a new class of metamaterial-inspired implantable ...
... 2010 How toxic, blue-green algae out-compete other organisms ... so doing proliferate dangerously in freshwater bodies -- has ... of Jerusalem. In general, the increasing occurrence ... is a matter of growing international concern due to ...
... Hematopoietic stem cells (HSCs) have two unique abilities that ... into any kind of blood cell, which enables them to ... these qualities to a distinct locale or niche within the ... and function of the niche-forming constituents have not been clearly ...
Cached Biology News:Implantable silk metamaterials could advance biomedicine, biosensing 2Implantable silk metamaterials could advance biomedicine, biosensing 3How algae 'enslavement' threatens freshwater bodies described by Hebrew University researcher 2Researchers find that one type of stem cell creates a niche for another type in bone marrow 2Researchers find that one type of stem cell creates a niche for another type in bone marrow 3
... lyophilization stabilizer is designed to stabilize ... for long-term storage. There are ... It is a convenient 10 ... and is superior to other traditional ...
... Techne TC-512 is the only Gradient thermal cycler ... the touch of a screen. ,Wide linear ... the market, with an amazing range of,30C. Protocols ... , TouchScreen - The Touchgene Gradient incorporates a ...
... The Freedom EVO Clinical is Tecans open ... to enhance quality, safety and performance in ... Safety is provided by flexible barcode reading ... to mention that the system complies with ...
Request Info...
Biology Products: